Literature DB >> 10399117

Long-term prognosis of Legg-Calvé-Perthes disease: a meta-analysis.

T Yrjönen1.   

Abstract

In the literature, long-term prognosis of Legg-Calvé-Perthes disease (LCPD) means prognosis for secondary osteoarthritis of the hip joint or leg-length inequality and its consequences. Most studies show results after conservative treatment. The long-term natural history of LCPD is not known. In spite of deformity, most patients do well in early adulthood. Radiographic and clinical osteoarthritis is increased in 20-year to 40-year follow-ups and degenerative joint disease develops in the majority of patients by the sixth or seventh decade of life. The reported average shortening of the affected leg has usually been 1 to 1.5 cm. There are no thorough long-term reports on low back pain after LCPD. The only evidence-based factors that are of prognostic importance in the long-term are age of the patient at the onset of the disease and shape of the femoral head at skeletal maturity.

Entities:  

Mesh:

Year:  1999        PMID: 10399117     DOI: 10.1097/01202412-199907000-00005

Source DB:  PubMed          Journal:  J Pediatr Orthop B        ISSN: 1060-152X            Impact factor:   1.041


  12 in total

1.  Low early failure rates using a surgical dislocation approach in healed Legg-Calvé-Perthes disease.

Authors:  Benjamin J Shore; Eduardo N Novais; Michael B Millis; Young-Jo Kim
Journal:  Clin Orthop Relat Res       Date:  2012-09       Impact factor: 4.176

2.  The long-term prognosis of Legg-Calvé-Perthes disease: a historical prospective study with a median follow-up of forty one years.

Authors:  Nicole Heesakkers; Robin van Kempen; Rhijn Feith; Jan Hendriks; Wim Schreurs
Journal:  Int Orthop       Date:  2014-11-19       Impact factor: 3.075

3.  Does surgical hip dislocation and periacetabular osteotomy improve pain in patients with Perthes-like deformities and acetabular dysplasia?

Authors:  John C Clohisy; Jeffrey J Nepple; James R Ross; Gail Pashos; Perry L Schoenecker
Journal:  Clin Orthop Relat Res       Date:  2015-04       Impact factor: 4.176

4.  Vasculature deprivation-induced osteonecrosis of rats' femoral heads associated with the formation of deep surface depressions.

Authors:  J Bejar; J H Boss
Journal:  Eur J Orthop Surg Traumatol       Date:  2006-02-10

5.  Unexpected MRI findings in clinically suspected Legg-Calvé-Perthes disease.

Authors:  Philip F Lobert; Jonathan R Dillman; Peter J Strouse; Ramiro J Hernandez
Journal:  Pediatr Radiol       Date:  2010-09-24

6.  Treatment outcome in the most severely affected Legg-Perthes patients, comparing prolonged traction in abduction with femoral varus derotation treatment.

Authors:  F B M Wagenaar; C G B Maathuis; R H G P van Erve
Journal:  J Child Orthop       Date:  2010-12-14       Impact factor: 1.548

7.  Joint-preserving surgery improves pain, range of motion, and abductor strength after Legg-Calvé-Perthes disease.

Authors:  Christoph Emanuel Albers; Simon Damian Steppacher; Reinhold Ganz; Klaus Arno Siebenrock; Moritz Tannast
Journal:  Clin Orthop Relat Res       Date:  2012-09       Impact factor: 4.176

8.  Tönnis triple pelvic osteotomy for Legg-Calve-Perthes disease.

Authors:  Ismet Yalkin Camurcu; Timur Yildirim; Abdul Fettah Buyuk; Sukru Sarper Gursu; Aysegul Bursali; Vedat Sahin
Journal:  Int Orthop       Date:  2014-11-25       Impact factor: 3.075

9.  Hip pain and mobility deficits--hip osteoarthritis: clinical practice guidelines linked to the international classification of functioning, disability, and health from the orthopaedic section of the American Physical Therapy Association.

Authors:  Michael T Cibulka; Douglas M White; Judith Woehrle; Marcie Harris-Hayes; Keelan Enseki; Timothy L Fagerson; James Slover; Joseph J Godges
Journal:  J Orthop Sports Phys Ther       Date:  2009-04       Impact factor: 4.751

10.  Legg-Calvé-Perthes disease affecting children less than eight years of age: a paired outcome study.

Authors:  S Sharma; S Shewale; M Sibinski; D A Sherlock
Journal:  Int Orthop       Date:  2008-01-09       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.